Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs

David H.M. Steffin, Ibrahim N. Muhsen, La Quisa C. Hill, Carlos A. Ramos, Nabil Ahmed, Meenakshi Hegde, Tao Wang, Mengfen Wu, Stephen Gottschalk, Sarah B. Whittle, Premal D. Lulla, Maksim Mamonkin, Bilal Omer, Rayne H. Rouce, Andras Heczey, Leonid S. Metelitsa, Bambi J. Grilley, Catherine Robertson, Virginia Torrano, Natalia LaptevaAdrian P. Gee, Cliona M. Rooney, Malcolm K. Brenner, Helen E. Heslop

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Subsequent malignancies are well-documented complications in long-term follow-up of cancer patients. Recently, genetically modified immune effector (IE) cells have shown benefit in hematologic malignancies and are being evaluated in clinical trials for solid tumors. Although the short-term complications of IE cells are well described, there is limited literature summarizing long-term follow-up, including subsequent malignancies. We retrospectively reviewed data from 340 patients treated across 27 investigator-initiated pediatric and adult clinical trials at our center. All patients received IE cells genetically modified with γ-retroviral vectors to treat relapsed and/or refractory hematologic or solid malignancies. In a cumulative 1027 years of long-term follow-up, 13 patients (3.8%) developed another cancer with a total of 16 events (4 hematologic malignancies and 12 solid tumors). The 5-year cumulative incidence of a first subsequent malignancy in the recipients of genetically modified IE cells was 3.6% (95% confidence interval, 1.8% to 6.4%). For 11 of the 16 subsequent tumors, biopsies were available, and no sample was transgene positive by polymerase chain reaction. Replication-competent retrovirus testing of peripheral blood mononuclear cells was negative in the 13 patients with subsequent malignancies tested. Rates of subsequent malignancy were low and comparable to standard chemotherapy. These results suggest that the administration of IE cells genetically modified with γ retroviral vectors does not increase the risk for subsequent malignancy.

Original languageEnglish (US)
Pages (from-to)16-24
Number of pages9
Issue number1
StatePublished - Jul 7 2022

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs'. Together they form a unique fingerprint.

Cite this